Paradigm Health secures funding and acquires Flatiron’s clinical research business

Paradigm Health, a US-based tech-enabled clinical research platform, has raised $78 million (€66.5m) in an oversubscribed Series B financing round and acquired the oncology-focused Clinical Research Business of Flatiron Health.

The acquisition adds a tech-enabled oncology research network and clinical research tools to Paradigm’s portfolio, while expanding its commercial reach into cardiovascular, metabolic, neuroscience, and other therapeutic areas.

The company’s platform connects patients, providers, and trial sponsors, using AI to automate patient matching and site feasibility. Following the acquisition, Paradigm’s platform will be available in 45 US states and integrated within 166 healthcare provider organisations, including 123 community oncology practices and 43 health systems and academic medical centres.

Paradigm and Flatiron Health have entered a multi-year strategic partnership to cross-integrate their platforms. The collaboration will see Flatiron’s tools incorporated into Paradigm’s technology, while Paradigm’s solutions are integrated into Flatiron’s OncoEMR, a cloud-based electronic medical record platform. Paradigm will also provide clinical research support to OncoEMR customers and Flatiron’s existing partner networks.

Nathan Hubbard, CEO of Flatiron Health, said: “This partnership brings together the strengths of both organizations. By combining Paradigm Health's AI-powered trial infrastructure with Flatiron's trusted network and support across academic and community oncology sites, we're building a stronger, more connected ecosystem for clinical research – expanding capabilities, accelerating impact and advancing our shared mission to bring new treatments to patients faster.”

The Series B investment, led by ARCH Venture Partners with participation from DFJ Growth, General Catalyst, GV, F-Prime, Lux Capital, Mubadala Capital, and the American Cancer Society’s BrightEdge Fund, will accelerate Paradigm’s expansion with global biopharmaceutical companies.

Explore how Paradigm Health is scaling oncology-focused clinical research and AI-enabled trial solutions across the US in the full story.